- SK pharmteco will invest $100 million to expand and strengthen its viral vector business across facilities in the U.S. and France.
- The company is advancing a three-business-unit strategy spanning small molecules, peptides, and viral vectors to support diverse biopharma pipelines.
SK pharmteco has announced a $100 million investment to support strategic initiatives within its viral vector business, while reinforcing its broader CDMO and contract manufacturing strategy across small molecules, peptides, and viral vectors.
The funding will be deployed to expand capabilities at the company’s viral vector centers of excellence in King of Prussia, Pennsylvania, and Corbeil-Essonnes, France. The investment is aimed at enhancing operational execution, strengthening quality systems, improving process performance, and advancing technology transfer across its global network.
The move reflects SK pharmteco’s focus on supporting pharmaceutical and biotechnology partners with infrastructure and expertise across multiple modalities. The company stated that its three-business-unit approach is designed to address increasingly complex and diverse pipelines, ranging from established therapies to advanced modalities such as viral vectors.
“Our strategy is built on the strength of three essential business units: small molecules, peptides, and viral vectors. As the industry evolves, our partners need a CDMO that combines specialized expertise, technical sophistication, and operational reliability across modalities.”
Joerg Ahlgrimm, Chief Executive Officer of SK pharmteco
By advancing this strategy, SK pharmteco aims to strengthen its position as a global CDMO, combining established small molecule manufacturing, peptide capabilities, and viral vector expertise to support development, late-stage, and commercial manufacturing programs.
